董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Reinhard J. Ambros | 男 | Director | 67 | 4.63万美元 | 未持股 | 2023-11-30 |
| Manuel C. Aivado | 男 | Chief Executive Officer, Director | 53 | 63.07万美元 | 未持股 | 2023-11-30 |
| Alan Musso | 男 | Director | 61 | 1.13万美元 | 未持股 | 2023-11-30 |
| William C. Fairey | 男 | Director | 59 | 0.94万美元 | 未持股 | 2023-11-30 |
| Nolan Sigal | 男 | Director | 73 | 5.55万美元 | 未持股 | 2023-11-30 |
| Josef H. von Rickenbach | 男 | Chairman of the Board | 68 | 6.80万美元 | 未持股 | 2023-11-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Manuel C. Aivado | 男 | Chief Executive Officer, Director | 53 | 63.07万美元 | 未持股 | 2023-11-30 |
| Brian Windsor | 男 | President and Chief Operating Officer | 57 | 8.53万美元 | 未持股 | 2023-11-30 |
| Susan L. Drexler | 女 | Interim Chief Financial Officer | 53 | 未披露 | 未持股 | 2023-11-30 |
董事简历
中英对照 | 中文 | 英文- Reinhard J. Ambros
-
Reinhard J. Ambros， 他是哲学博士。他担任Aileron Therapeutics, Inc.的董事（2009年5月以来）。他曾担任Novartis Venture Funds的全球负责人（2005年8月以来）。此前，他曾担任Novartis Corporation的集团战略规划的负责人（从2001年到2005年）。此前，他曾担任Novartis Pharma公司的心血管和代谢疾病的业务开发和许可的全球负责人。目前，他担任Aileron公司、FORMA Therapeutics公司、Genedata公司、Symetis公司的董事会成员。他持有the University of Regensburg（位于德国）的硕士学位，以及the University of Regensburg（位于德国）的药物化学和药理学博士学位。
Reinhard J. Ambros,has served as a member of Aileron Therapeutics, Inc. board of directors since June 2013. From 2005 until 2017, Dr. Ambros served as global head of Novartis Venture Funds, a globally acting corporate biotechnology venture fund. Prior to that, from 1999 until 2005, he served as head of group strategic planning and as global head of business development and licensing for cardiovascular and metabolic diseases at Novartis AG, a multinational pharmaceutical company. He currently serves on the boards of several biotechnology companies in Europe and the U.S. He also served as advisor to German and Swiss Government Biotechnology Funds. Dr. Ambros received an M.S. from the University of Regensburg, Germany, and a Ph.D. in medicinal chemistry and pharmacology from the University of Regensburg, Germany. - Reinhard J. Ambros， 他是哲学博士。他担任Aileron Therapeutics, Inc.的董事（2009年5月以来）。他曾担任Novartis Venture Funds的全球负责人（2005年8月以来）。此前，他曾担任Novartis Corporation的集团战略规划的负责人（从2001年到2005年）。此前，他曾担任Novartis Pharma公司的心血管和代谢疾病的业务开发和许可的全球负责人。目前，他担任Aileron公司、FORMA Therapeutics公司、Genedata公司、Symetis公司的董事会成员。他持有the University of Regensburg（位于德国）的硕士学位，以及the University of Regensburg（位于德国）的药物化学和药理学博士学位。
- Reinhard J. Ambros,has served as a member of Aileron Therapeutics, Inc. board of directors since June 2013. From 2005 until 2017, Dr. Ambros served as global head of Novartis Venture Funds, a globally acting corporate biotechnology venture fund. Prior to that, from 1999 until 2005, he served as head of group strategic planning and as global head of business development and licensing for cardiovascular and metabolic diseases at Novartis AG, a multinational pharmaceutical company. He currently serves on the boards of several biotechnology companies in Europe and the U.S. He also served as advisor to German and Swiss Government Biotechnology Funds. Dr. Ambros received an M.S. from the University of Regensburg, Germany, and a Ph.D. in medicinal chemistry and pharmacology from the University of Regensburg, Germany.
- Manuel C. Aivado
-
ManuelC.Aivado自2014年9月起担任高级副总裁，首席医疗官。2012年3月至2014年9月，Aivado博士担任制药公司Taiho Oncology，Inc.的临床开发和药物警戒Vice President。从2006年10月到2012年3月，Aivado博士担任葛兰素史克公司（GlaxoSmithKline，Inc.）临床开发集团的高级医疗总监，该公司是一家全球制药公司。此外，Aivado博士曾是Beth Israel Deaconess Medical Center/Harvard Medical School的医学讲师。在他的行业经验之前，Aivado博士在德国从事临床医学十年，在此期间他于2002年被授予米尔德里德·舍尔博士癌症研究奖学金。Aivado博士是德国委员会认证的内科、血液学和医疗肿瘤学医师，他在德国杜塞尔多夫大学医学院（University of Dusseldorf）获得医学博士学位和博士学位。
Manuel C. Aivado,has served as Aileron Therapeutics, Inc. chief executive officer and as a member of Aileron Therapeutics, Inc. board of directors since September 2018. Previously, Dr. Aivado served as Aileron Therapeutics, Inc. president from September 2018 to October 2023, and senior vice president, chief medical officer from September 2014 to September 2018. From March 2012 to September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 to March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. Dr. Aivado has also served as an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years. During that time, he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology, and medical oncology. He received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf in Germany. - ManuelC.Aivado自2014年9月起担任高级副总裁，首席医疗官。2012年3月至2014年9月，Aivado博士担任制药公司Taiho Oncology，Inc.的临床开发和药物警戒Vice President。从2006年10月到2012年3月，Aivado博士担任葛兰素史克公司（GlaxoSmithKline，Inc.）临床开发集团的高级医疗总监，该公司是一家全球制药公司。此外，Aivado博士曾是Beth Israel Deaconess Medical Center/Harvard Medical School的医学讲师。在他的行业经验之前，Aivado博士在德国从事临床医学十年，在此期间他于2002年被授予米尔德里德·舍尔博士癌症研究奖学金。Aivado博士是德国委员会认证的内科、血液学和医疗肿瘤学医师，他在德国杜塞尔多夫大学医学院（University of Dusseldorf）获得医学博士学位和博士学位。
- Manuel C. Aivado,has served as Aileron Therapeutics, Inc. chief executive officer and as a member of Aileron Therapeutics, Inc. board of directors since September 2018. Previously, Dr. Aivado served as Aileron Therapeutics, Inc. president from September 2018 to October 2023, and senior vice president, chief medical officer from September 2014 to September 2018. From March 2012 to September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 to March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. Dr. Aivado has also served as an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years. During that time, he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology, and medical oncology. He received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf in Germany.
- Alan Musso
-
Alan Musso，自2023年10月起担任Aileron Therapeutics董事会成员。自2023年8月以来，Musso先生担任Fulcrum Therapeutics的首席财务官，该公司是一家公共临床阶段的生物制药公司，专注于改善基因定义的罕见病患者在医疗需求高度未满足领域的生活。此前，他担任ReViral Ltd.的首席财务官，该公司是一家私营的临床阶段生物制药公司，专注于发现、开发和商业化针对呼吸道合胞病毒（RSV）的新型抗病毒疗法，该公司于2022年6月被辉瑞公司收购，时间为2019年10月至2022年9月。在加入ReViral之前，从2018年9月到2019年9月，Musso先生在Peloton治疗公司担任首席财务官兼财务主管，该公司专注于开发用于治疗癌症的新型小分子治疗候选药物。在Peloton期间，Musso先生帮助公司为首次公开募股做准备，直到该公司于2019年7月被默沙东公司收购。在加入Peloton之前，2014年11月至2018年8月，Musso先生在Bellicum制药公司担任首席财务官和财务主管，这是一家上市生物技术公司，专注于发现和开发针对各种形式癌症的新型、可控细胞免疫疗法。在加入Bellicum之前，从2002年2月到2014年11月，Musso先生曾在Targacept，Inc.担任多个职位，Targacept，Inc.是一家上市生物制药公司。Musso先生在其职业生涯的早期曾担任辉瑞的高级内部审计师以及毕马威国际会计师事务所的注册会计师。Musso先生自2022年4月起担任Lung董事会成员，直至Lung收购于2023年10月完成。Musso先生拥有加州圣玛丽学院会计学学士学位和雷鸟全球管理学院硕士学位。
Alan Musso,has served as a member of Aileron Therapeutics, Inc. board of directors since October 2023. Since August 2023, Mr. Musso has served as the chief financial officer of Fulcrum Therapeutics, a public clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Previously, he served as the chief financial officer of ReViral Ltd., a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), that was acquired by Pfizer Inc., in June 2022, from October 2019 until September 2022. Prior to ReViral, from September 2018 to September 2019, Mr. Musso was the chief financial officer and treasurer at Peloton Therapeutics Inc., a company focused on the development of novel small molecule therapeutic candidates for the treatment of cancer. While at Peloton, Mr. Musso helped to prepare the company for an initial public offering until the company was acquired by Merck & Co. in July 2019. Prior to Peloton, from November 2014 to August 2018, Mr. Musso served as the chief financial officer and treasurer at Bellicum Pharmaceuticals, Inc., a public biotechnology company focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer. Prior to Bellicum, from February 2002 to November 2014, Mr. Musso served in various positions at Targacept, Inc., a public biopharmaceutical company. Mr. Musso spent the early part of his career as a senior internal auditor for Pfizer as well as a certified public accountant for KPMG International. Mr. Musso served as a member of the board of directors of Lung from April 2022 until the closing of the Lung Acquisition in October 2023. Mr. Musso holds a B.S. in accounting from Saint Mary's College of California, and a Master's Degree from the Thunderbird School of Global Management. - Alan Musso，自2023年10月起担任Aileron Therapeutics董事会成员。自2023年8月以来，Musso先生担任Fulcrum Therapeutics的首席财务官，该公司是一家公共临床阶段的生物制药公司，专注于改善基因定义的罕见病患者在医疗需求高度未满足领域的生活。此前，他担任ReViral Ltd.的首席财务官，该公司是一家私营的临床阶段生物制药公司，专注于发现、开发和商业化针对呼吸道合胞病毒（RSV）的新型抗病毒疗法，该公司于2022年6月被辉瑞公司收购，时间为2019年10月至2022年9月。在加入ReViral之前，从2018年9月到2019年9月，Musso先生在Peloton治疗公司担任首席财务官兼财务主管，该公司专注于开发用于治疗癌症的新型小分子治疗候选药物。在Peloton期间，Musso先生帮助公司为首次公开募股做准备，直到该公司于2019年7月被默沙东公司收购。在加入Peloton之前，2014年11月至2018年8月，Musso先生在Bellicum制药公司担任首席财务官和财务主管，这是一家上市生物技术公司，专注于发现和开发针对各种形式癌症的新型、可控细胞免疫疗法。在加入Bellicum之前，从2002年2月到2014年11月，Musso先生曾在Targacept，Inc.担任多个职位，Targacept，Inc.是一家上市生物制药公司。Musso先生在其职业生涯的早期曾担任辉瑞的高级内部审计师以及毕马威国际会计师事务所的注册会计师。Musso先生自2022年4月起担任Lung董事会成员，直至Lung收购于2023年10月完成。Musso先生拥有加州圣玛丽学院会计学学士学位和雷鸟全球管理学院硕士学位。
- Alan Musso,has served as a member of Aileron Therapeutics, Inc. board of directors since October 2023. Since August 2023, Mr. Musso has served as the chief financial officer of Fulcrum Therapeutics, a public clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Previously, he served as the chief financial officer of ReViral Ltd., a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), that was acquired by Pfizer Inc., in June 2022, from October 2019 until September 2022. Prior to ReViral, from September 2018 to September 2019, Mr. Musso was the chief financial officer and treasurer at Peloton Therapeutics Inc., a company focused on the development of novel small molecule therapeutic candidates for the treatment of cancer. While at Peloton, Mr. Musso helped to prepare the company for an initial public offering until the company was acquired by Merck & Co. in July 2019. Prior to Peloton, from November 2014 to August 2018, Mr. Musso served as the chief financial officer and treasurer at Bellicum Pharmaceuticals, Inc., a public biotechnology company focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer. Prior to Bellicum, from February 2002 to November 2014, Mr. Musso served in various positions at Targacept, Inc., a public biopharmaceutical company. Mr. Musso spent the early part of his career as a senior internal auditor for Pfizer as well as a certified public accountant for KPMG International. Mr. Musso served as a member of the board of directors of Lung from April 2022 until the closing of the Lung Acquisition in October 2023. Mr. Musso holds a B.S. in accounting from Saint Mary's College of California, and a Master's Degree from the Thunderbird School of Global Management.
- William C. Fairey
-
William C. Fairey，自2023年10月起担任Aileron Therapeutics董事会成员。Fairey先生曾于2019年1月至2020年11月担任MyoKardia，Inc.的执行副总裁兼首席商务官，该公司是一家临床阶段的生物制药公司，发现并开发用于治疗严重心血管疾病的靶向疗法，此前该公司于2020年10月被百时美施贵宝收购。在加入MyoKardia之前，2018年1月至2019年1月，Fairey先生担任ChemoCentryx公司执行副总裁兼首席运营官，该公司是一家上市生物制药公司，专注于发现、开发口服疗法并将其商业化，以治疗自身免疫性疾病、炎症性疾病和癌症。在此期间，Fairey先生负责销售、市场营销、医疗事务和市场准入职能，包括后期化合物的商业化。在加入ChemoCentryx之前，Fairey先生曾于2001年1月至2017年12月在制药公司Actelion Pharmaceuticals Ltd.及其子公司担任过各种职务。Actelion于2017年被强生收购。Fairey先生自2021年8月起担任Mirum制药的董事会成员，该公司是一家上市生物制药公司，专注于识别、收购、开发和商业化治疗使人衰弱的罕见和孤儿疾病的新疗法，并自2022年8月起担任Ascendis Pharma A/S的董事会成员，该公司是一家根据丹麦王国法律组建的上市生物制药公司。Fairey先生自2021年8月起担任Lung董事会成员，直至Lung收购于2023年10月完成。Fairey先生拥有俄勒冈大学生物学学士学位和加州圣玛丽学院工商管理硕士学位。
William C. Fairey,has served as a member of Aileron Therapeutics, Inc. board of directors since October 2023. Mr. Fairey served as executive vice president and chief commercial officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, from January 2019 to November 2020 prior to its acquisition by Bristol Myers Squibb in October 2020. Prior to MyoKardia, from January 2018 to January 2019, Mr. Fairey served as executive vice president and chief operating officer of ChemoCentryx, Inc., a public biopharmaceutical company focused on discovering, developing and commercializing orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. During that time, Mr. Fairey was responsible for the sales, marketing, medical affairs and market access functions, including commercialization of late stages compounds. Prior to ChemoCentryx, Mr. Fairey served in various roles at Actelion Pharmaceuticals Ltd., a pharmaceutical company, and its subsidiaries, from January 2001 to December 2017. Actelion was acquired by Johnson & Johnson in 2017. Mr. Fairey has served on the board of directors of Mirum Pharmaceuticals, a public biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, since August 2021 and on the board of directors of Ascendis Pharma A/S, a public biopharmaceutical company organized under the laws of the Kingdom of Denmark, since August 2022. Mr. Fairey served as a member of the board of directors of Lung from August 2021 until the closing of the Lung Acquisition in October 2023. Mr. Fairey holds a B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary's College of California. - William C. Fairey，自2023年10月起担任Aileron Therapeutics董事会成员。Fairey先生曾于2019年1月至2020年11月担任MyoKardia，Inc.的执行副总裁兼首席商务官，该公司是一家临床阶段的生物制药公司，发现并开发用于治疗严重心血管疾病的靶向疗法，此前该公司于2020年10月被百时美施贵宝收购。在加入MyoKardia之前，2018年1月至2019年1月，Fairey先生担任ChemoCentryx公司执行副总裁兼首席运营官，该公司是一家上市生物制药公司，专注于发现、开发口服疗法并将其商业化，以治疗自身免疫性疾病、炎症性疾病和癌症。在此期间，Fairey先生负责销售、市场营销、医疗事务和市场准入职能，包括后期化合物的商业化。在加入ChemoCentryx之前，Fairey先生曾于2001年1月至2017年12月在制药公司Actelion Pharmaceuticals Ltd.及其子公司担任过各种职务。Actelion于2017年被强生收购。Fairey先生自2021年8月起担任Mirum制药的董事会成员，该公司是一家上市生物制药公司，专注于识别、收购、开发和商业化治疗使人衰弱的罕见和孤儿疾病的新疗法，并自2022年8月起担任Ascendis Pharma A/S的董事会成员，该公司是一家根据丹麦王国法律组建的上市生物制药公司。Fairey先生自2021年8月起担任Lung董事会成员，直至Lung收购于2023年10月完成。Fairey先生拥有俄勒冈大学生物学学士学位和加州圣玛丽学院工商管理硕士学位。
- William C. Fairey,has served as a member of Aileron Therapeutics, Inc. board of directors since October 2023. Mr. Fairey served as executive vice president and chief commercial officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, from January 2019 to November 2020 prior to its acquisition by Bristol Myers Squibb in October 2020. Prior to MyoKardia, from January 2018 to January 2019, Mr. Fairey served as executive vice president and chief operating officer of ChemoCentryx, Inc., a public biopharmaceutical company focused on discovering, developing and commercializing orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. During that time, Mr. Fairey was responsible for the sales, marketing, medical affairs and market access functions, including commercialization of late stages compounds. Prior to ChemoCentryx, Mr. Fairey served in various roles at Actelion Pharmaceuticals Ltd., a pharmaceutical company, and its subsidiaries, from January 2001 to December 2017. Actelion was acquired by Johnson & Johnson in 2017. Mr. Fairey has served on the board of directors of Mirum Pharmaceuticals, a public biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, since August 2021 and on the board of directors of Ascendis Pharma A/S, a public biopharmaceutical company organized under the laws of the Kingdom of Denmark, since August 2022. Mr. Fairey served as a member of the board of directors of Lung from August 2021 until the closing of the Lung Acquisition in October 2023. Mr. Fairey holds a B.S. in biology from the University of Oregon and an M.B.A. from Saint Mary's College of California.
- Nolan Sigal
-
Nolan Sigal，自2019年4月起担任Aileron Therapeutics董事会成员。Sigal博士自2018年1月起担任私人投资公司Alerce Management Co.，L.P.的合伙人。2008年3月至2017年12月，Sigal博士是生物制药公司Tunitas Therapeutics，Inc.的创始人兼首席执行官。在加入Tunitas之前，Sigal博士的生物技术经验包括生物技术公司Trellis Bioscience，Inc.的总裁、生物制药公司Cytokinetics公司的研发执行副总裁和首席科学官，以及生物技术公司Pharmacopeia，Inc.的研究高级副总裁，他是Pharmacopeia的创始人之一。他曾任职于默沙东公司，担任免疫学研究部执行主任。在加入默沙东之前，他是多伦多大学的助理教授。Sigal博士毕业于普林斯顿大学化学A.B.，他在宾夕法尼亚大学完成了医学博士/博士课程。
Nolan Sigal,has served as a member of Aileron Therapeutics, Inc. board of directors since April 2019. Dr. Sigal has served as a partner at Alerce Management Co., L.P., a private investment firm, since January 2018. From March 2008 to December 2017, Dr. Sigal was founder and chief executive officer of Tunitas Therapeutics, Inc., a biopharmaceutical company. Prior to Tunitas, Dr. Sigal's biotechnology experience included president of Trellis Bioscience, Inc., a biotechnology company, EVP of research and development, and chief scientific officer at Cytokinetics, Inc., a biopharmaceutical company, and SVP, research at Pharmacopeia, Inc., a biotechnology company, where he was one of Pharmacopeia's founders. He served at Merck & Company Inc. as executive director of the Department of Immunology Research. Prior to Merck, he was an assistant professor at the University of Toronto. Dr. Sigal graduated from Princeton University with an A.B. in chemistry, and he completed an M.D./Ph.D. program at the University of Pennsylvania. - Nolan Sigal，自2019年4月起担任Aileron Therapeutics董事会成员。Sigal博士自2018年1月起担任私人投资公司Alerce Management Co.，L.P.的合伙人。2008年3月至2017年12月，Sigal博士是生物制药公司Tunitas Therapeutics，Inc.的创始人兼首席执行官。在加入Tunitas之前，Sigal博士的生物技术经验包括生物技术公司Trellis Bioscience，Inc.的总裁、生物制药公司Cytokinetics公司的研发执行副总裁和首席科学官，以及生物技术公司Pharmacopeia，Inc.的研究高级副总裁，他是Pharmacopeia的创始人之一。他曾任职于默沙东公司，担任免疫学研究部执行主任。在加入默沙东之前，他是多伦多大学的助理教授。Sigal博士毕业于普林斯顿大学化学A.B.，他在宾夕法尼亚大学完成了医学博士/博士课程。
- Nolan Sigal,has served as a member of Aileron Therapeutics, Inc. board of directors since April 2019. Dr. Sigal has served as a partner at Alerce Management Co., L.P., a private investment firm, since January 2018. From March 2008 to December 2017, Dr. Sigal was founder and chief executive officer of Tunitas Therapeutics, Inc., a biopharmaceutical company. Prior to Tunitas, Dr. Sigal's biotechnology experience included president of Trellis Bioscience, Inc., a biotechnology company, EVP of research and development, and chief scientific officer at Cytokinetics, Inc., a biopharmaceutical company, and SVP, research at Pharmacopeia, Inc., a biotechnology company, where he was one of Pharmacopeia's founders. He served at Merck & Company Inc. as executive director of the Department of Immunology Research. Prior to Merck, he was an assistant professor at the University of Toronto. Dr. Sigal graduated from Princeton University with an A.B. in chemistry, and he completed an M.D./Ph.D. program at the University of Pennsylvania.
- Josef H. von Rickenbach
-
Josef H. von Rickenbach于1982年创立Parexel International Corporation，自1983年起担任公司董事、董事长兼首席执行官。1983年至2001年4月，2005年7月至2012年7月，他担任总裁。他也曾在Schering-Plough, Inc.、3M East (3M Company的一个部门)和ERCO(后来的ENSECO)， Inc.(一家多元化的测试和技术咨询公司)工作。他曾于2005年和2013年担任专业行业组织临床研究组织协会(ACRO)主席，并担任其董事会成员12年。他是NEHI(卓越健康创新网络)的董事会成员和提名委员会主席。他获得了哈佛商学院的工商管理硕士学位和 Lucerne University of Applied Sciences and Arts in Switzerland的商业经济学学士学位。
Josef H. von Rickenbach,has served as a member of Aileron Therapeutics, Inc. board of directors since June 2019. Mr. von Rickenbach has served as managing director of Stet Vision LLC, a life sciences business advisory firm, since December 2018. He co-founded and served as president and chief executive officer of HelioVision, Inc., a biotechnology company, from April 2017 until its acquisition by Aldeyra Therapeutics, Inc. in February 2019. Previously, Mr. von Rickenbach was a founder of Parexel International Corporation, a global clinical research organization and biopharmaceutical services company, in 1982 and served as a director, chairman of the board, and chief executive officer of Parexel from 1983 until the company's acquisition by Pamplona Capital Management, LLP in September 2017. Mr. von Rickenbach received an M.B.A. from Harvard Business School and a B.A. in business economics from the University of Lucerne in Switzerland. - Josef H. von Rickenbach于1982年创立Parexel International Corporation，自1983年起担任公司董事、董事长兼首席执行官。1983年至2001年4月，2005年7月至2012年7月，他担任总裁。他也曾在Schering-Plough, Inc.、3M East (3M Company的一个部门)和ERCO(后来的ENSECO)， Inc.(一家多元化的测试和技术咨询公司)工作。他曾于2005年和2013年担任专业行业组织临床研究组织协会(ACRO)主席，并担任其董事会成员12年。他是NEHI(卓越健康创新网络)的董事会成员和提名委员会主席。他获得了哈佛商学院的工商管理硕士学位和 Lucerne University of Applied Sciences and Arts in Switzerland的商业经济学学士学位。
- Josef H. von Rickenbach,has served as a member of Aileron Therapeutics, Inc. board of directors since June 2019. Mr. von Rickenbach has served as managing director of Stet Vision LLC, a life sciences business advisory firm, since December 2018. He co-founded and served as president and chief executive officer of HelioVision, Inc., a biotechnology company, from April 2017 until its acquisition by Aldeyra Therapeutics, Inc. in February 2019. Previously, Mr. von Rickenbach was a founder of Parexel International Corporation, a global clinical research organization and biopharmaceutical services company, in 1982 and served as a director, chairman of the board, and chief executive officer of Parexel from 1983 until the company's acquisition by Pamplona Capital Management, LLP in September 2017. Mr. von Rickenbach received an M.B.A. from Harvard Business School and a B.A. in business economics from the University of Lucerne in Switzerland.
高管简历
中英对照 | 中文 | 英文- Manuel C. Aivado
ManuelC.Aivado自2014年9月起担任高级副总裁，首席医疗官。2012年3月至2014年9月，Aivado博士担任制药公司Taiho Oncology，Inc.的临床开发和药物警戒Vice President。从2006年10月到2012年3月，Aivado博士担任葛兰素史克公司（GlaxoSmithKline，Inc.）临床开发集团的高级医疗总监，该公司是一家全球制药公司。此外，Aivado博士曾是Beth Israel Deaconess Medical Center/Harvard Medical School的医学讲师。在他的行业经验之前，Aivado博士在德国从事临床医学十年，在此期间他于2002年被授予米尔德里德·舍尔博士癌症研究奖学金。Aivado博士是德国委员会认证的内科、血液学和医疗肿瘤学医师，他在德国杜塞尔多夫大学医学院（University of Dusseldorf）获得医学博士学位和博士学位。
Manuel C. Aivado,has served as Aileron Therapeutics, Inc. chief executive officer and as a member of Aileron Therapeutics, Inc. board of directors since September 2018. Previously, Dr. Aivado served as Aileron Therapeutics, Inc. president from September 2018 to October 2023, and senior vice president, chief medical officer from September 2014 to September 2018. From March 2012 to September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 to March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. Dr. Aivado has also served as an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years. During that time, he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology, and medical oncology. He received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf in Germany.- ManuelC.Aivado自2014年9月起担任高级副总裁，首席医疗官。2012年3月至2014年9月，Aivado博士担任制药公司Taiho Oncology，Inc.的临床开发和药物警戒Vice President。从2006年10月到2012年3月，Aivado博士担任葛兰素史克公司（GlaxoSmithKline，Inc.）临床开发集团的高级医疗总监，该公司是一家全球制药公司。此外，Aivado博士曾是Beth Israel Deaconess Medical Center/Harvard Medical School的医学讲师。在他的行业经验之前，Aivado博士在德国从事临床医学十年，在此期间他于2002年被授予米尔德里德·舍尔博士癌症研究奖学金。Aivado博士是德国委员会认证的内科、血液学和医疗肿瘤学医师，他在德国杜塞尔多夫大学医学院（University of Dusseldorf）获得医学博士学位和博士学位。
- Manuel C. Aivado,has served as Aileron Therapeutics, Inc. chief executive officer and as a member of Aileron Therapeutics, Inc. board of directors since September 2018. Previously, Dr. Aivado served as Aileron Therapeutics, Inc. president from September 2018 to October 2023, and senior vice president, chief medical officer from September 2014 to September 2018. From March 2012 to September 2014, Dr. Aivado served as vice president of clinical development and pharmacovigilance at Taiho Oncology, Inc., a pharmaceutical company. From October 2006 to March 2012, Dr. Aivado served as senior medical director in the clinical development group at GlaxoSmithKline, Inc., a global pharmaceutical company. Dr. Aivado has also served as an instructor in medicine at Beth Israel Deaconess Medical Center/Harvard Medical School. Prior to his industry experience, Dr. Aivado practiced clinical medicine in Germany for nearly ten years. During that time, he was awarded the Dr. Mildred Scheel cancer research scholarship award in 2002. Dr. Aivado is a German board-certified physician for internal medicine, hematology, and medical oncology. He received an M.D. and Ph.D. from the Medical School of the University of Dusseldorf in Germany.
- Brian Windsor
Brian Windsor自2018年1月起担任董事会成员，自2019年9月起担任首席科学官。在2018年1月至2019年9月期间，温莎博士为我们提供了科学和技术领域的咨询服务。他目前是Lung Therapeutics，Inc.（LTI）的总裁、首席执行官和董事会成员（2013年7月以来）。从2009年11月到2013年3月，他曾担任Enavail公司（专业制药公司）的总裁，在那里他曾监管公司的制药药物开发的所有方面。加入Enavail公司之前，他曾领导Emergent Technologies公司（早期技术风险创建和管理公司）的投资组合公司管理，在那里他曾担任10个投资组合公司的董事总经理或总裁。他持有德克萨斯大学奥斯汀分校（the University of Texas at Austin）的分子生物学博士学位，是科学和技术转让活动的特邀演讲人，也是多项专利和专利申请的发明人。
Brian Windsor has served as a member of our Board since January 2018 and as our Chief Science Officer since September 2019. Between January 2018 and September 2019 Dr. Windsor provided consulting services to us in the areas of science and technology. Dr Windsor is currently the President, Chief Executive Officer and a member of the board of directors of Lung Therapeutics, Inc., or LTI, positions he has held since July 2013. From November 2009 to March 2013 Dr. Windsor served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies, Inc., an early stage technology venture creation and management company, where he served as Managing Director or President for ten portfolio companies. He holds a Ph.D. in Molecular Biology from The University of Texas at Austin, is an invited speaker for both scientific and technology transfer events, and is an inventor on multiple patents and patent applications.- Brian Windsor自2018年1月起担任董事会成员，自2019年9月起担任首席科学官。在2018年1月至2019年9月期间，温莎博士为我们提供了科学和技术领域的咨询服务。他目前是Lung Therapeutics，Inc.（LTI）的总裁、首席执行官和董事会成员（2013年7月以来）。从2009年11月到2013年3月，他曾担任Enavail公司（专业制药公司）的总裁，在那里他曾监管公司的制药药物开发的所有方面。加入Enavail公司之前，他曾领导Emergent Technologies公司（早期技术风险创建和管理公司）的投资组合公司管理，在那里他曾担任10个投资组合公司的董事总经理或总裁。他持有德克萨斯大学奥斯汀分校（the University of Texas at Austin）的分子生物学博士学位，是科学和技术转让活动的特邀演讲人，也是多项专利和专利申请的发明人。
- Brian Windsor has served as a member of our Board since January 2018 and as our Chief Science Officer since September 2019. Between January 2018 and September 2019 Dr. Windsor provided consulting services to us in the areas of science and technology. Dr Windsor is currently the President, Chief Executive Officer and a member of the board of directors of Lung Therapeutics, Inc., or LTI, positions he has held since July 2013. From November 2009 to March 2013 Dr. Windsor served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies, Inc., an early stage technology venture creation and management company, where he served as Managing Director or President for ten portfolio companies. He holds a Ph.D. in Molecular Biology from The University of Texas at Austin, is an invited speaker for both scientific and technology transfer events, and is an inventor on multiple patents and patent applications.
- Susan L. Drexler
Susan L.Drexler自2019年10月起担任我们的首席财务官。从2018年4月至2019年6月，德雷克斯勒女士担任Ocugen，Inc.业务发展临时首席财务官兼Vice President2015年8月至2017年11月，德雷克斯勒女士在美源伯根公司担任业务开发和市场情报方面的高级职位。从2007年7月到2015年6月，Drexler女士在Shire Pharmaceuticals担任高级开发财务职位。在她职业生涯的早期，Drexler女士在Duff&Phelps，LLC担任财务咨询职责递增的职位，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）担任高级审计职位。Drexler女士在奥尔布赖特学院（Albright College）获得会计学学士学位，并在匹兹堡大学（University of Pittsburgh）约瑟夫·卡茨商学院（Joseph M.Katz Graduate School of Business）获得工商管理硕士学位。Drexler女士是宾夕法尼亚州的注册会计师。
Susan L. Drexler,has served as Aileron Therapeutics, Inc. interim chief financial officer since June 2022. Since January 2022, Ms. Drexler has served as a chief financial officer consultant at Danforth Advisors, a firm that specializes in outsourced corporate functions for life sciences companies. From October 2019 to March 2021, Ms. Drexler served as chief financial officer at Harmony Biosciences, a life sciences company. From April 2018 to June 2019, Ms. Drexler served in various roles as interim chief financial officer and vice president of business development at Ocugen, Inc., a biotechnology company. From August 2015 to November 2017, Ms. Drexler served in senior roles in business development and market intelligence at AmerisourceBergen Corporation, a company that provides distribution, logistics and technology solutions to life sciences companies. From July 2007 to June 2015, Ms. Drexler held a senior business development finance role at Shire Pharmaceuticals, a biopharmaceutical company. Earlier in her career, Ms. Drexler held roles of increasing responsibility in finance consulting at Duff & Phelps, LLC, a financial consultancy firm, and senior audit roles at PricewaterhouseCoopers. Ms. Drexler earned a B.S. in Accounting from Albright College and an M.B.A. from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Ms. Drexler is a Certified Public Accountant in the State of Pennsylvania.- Susan L.Drexler自2019年10月起担任我们的首席财务官。从2018年4月至2019年6月，德雷克斯勒女士担任Ocugen，Inc.业务发展临时首席财务官兼Vice President2015年8月至2017年11月，德雷克斯勒女士在美源伯根公司担任业务开发和市场情报方面的高级职位。从2007年7月到2015年6月，Drexler女士在Shire Pharmaceuticals担任高级开发财务职位。在她职业生涯的早期，Drexler女士在Duff&Phelps，LLC担任财务咨询职责递增的职位，并在普华永道会计师事务所（PricewaterhouseCoopers LLP）担任高级审计职位。Drexler女士在奥尔布赖特学院（Albright College）获得会计学学士学位，并在匹兹堡大学（University of Pittsburgh）约瑟夫·卡茨商学院（Joseph M.Katz Graduate School of Business）获得工商管理硕士学位。Drexler女士是宾夕法尼亚州的注册会计师。
- Susan L. Drexler,has served as Aileron Therapeutics, Inc. interim chief financial officer since June 2022. Since January 2022, Ms. Drexler has served as a chief financial officer consultant at Danforth Advisors, a firm that specializes in outsourced corporate functions for life sciences companies. From October 2019 to March 2021, Ms. Drexler served as chief financial officer at Harmony Biosciences, a life sciences company. From April 2018 to June 2019, Ms. Drexler served in various roles as interim chief financial officer and vice president of business development at Ocugen, Inc., a biotechnology company. From August 2015 to November 2017, Ms. Drexler served in senior roles in business development and market intelligence at AmerisourceBergen Corporation, a company that provides distribution, logistics and technology solutions to life sciences companies. From July 2007 to June 2015, Ms. Drexler held a senior business development finance role at Shire Pharmaceuticals, a biopharmaceutical company. Earlier in her career, Ms. Drexler held roles of increasing responsibility in finance consulting at Duff & Phelps, LLC, a financial consultancy firm, and senior audit roles at PricewaterhouseCoopers. Ms. Drexler earned a B.S. in Accounting from Albright College and an M.B.A. from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Ms. Drexler is a Certified Public Accountant in the State of Pennsylvania.